Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.

Robert J Motzer Axel BexPaul RussoYoshihiko TomitaHernan Javier CutuliCarlos RojasMarine Gross-GoupilGiovanni SchinzariBohuslav MelicharPhilippe BarthélémyAbraham Ruiz GarciaJeffrey SosmanMarc-Oliver Grimm Jeffrey C GohCristina SuarezChristian K Kollmannsberger Suresh G Nair Brian M ShuchJian HuangBurcin SimsekJulia SpiridigliozziChung-Wei LeeMaximiliano van Kooten LosioViktor Gruenwald

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

Part B of CheckMate 914 did not meet the primary end point of improved DFS for nivolumab versus placebo in patients with localized RCC at high risk of postnephrectomy recurrence.

Keyphrases

phase iii
placebo controlled
renal cell carcinoma
double blind
open label
phase ii
clinical trial
study protocol
early stage
robot assisted
phase ii study
free survival
randomized controlled trial
editorial comment
minimally invasive
radiation therapy
squamous cell carcinoma